SAPPERN MATTHEW DAVID 4

Accession 0001209191-10-044028

CIK 0001034088other

View on SEC.gov Company Profile

Filed

Aug 25, 8:00 PM ET

Accepted

Aug 26, 2:37 PM ET

Size

34.2 KB

Accession

0001209191-10-044028

Insider Transaction Report

Form 4

Period: 2010-08-24

ECLIPSYS CORPECLP

SAPPERN MATTHEW DAVID

SVP, Professional Services

Transactions

Disposition to Issuer
Stock Options
2010-08-24−50,000→ 0 total
Exercise: $25.12→ Common Stock (50,000 underlying)
Disposition to Issuer
Stock Options
2010-08-24−15,000→ 0 total
Exercise: $7.97→ Common Stock (15,000 underlying)
Disposition to Issuer
Common Stock
2010-08-24−10,714→ 0 total
Disposition to Issuer
Stock Options
2010-08-24−13,591→ 0 total
Exercise: $13.35→ Common Stock (13,591 underlying)
Disposition to Issuer
Stock Options
2010-08-24−3,750→ 0 total
Exercise: $1577.00→ Common Stock (3,750 underlying)
Disposition to Issuer
Stock Options
2010-08-24−7,250→ 0 total
Exercise: $15.77→ Common Stock (7,250 underlying)
Disposition to Issuer
Stock Options
2010-08-24−14,000→ 0 total
Exercise: $22.07→ Common Stock (14,000 underlying)
Disposition to Issuer
Stock Options
2010-08-24−3,600→ 0 total
Exercise: $10.05→ Common Stock (3,600 underlying)
Disposition to Issuer
Stock Options
2010-08-24−10,000→ 0 total
Exercise: $22.29→ Common Stock (10,000 underlying)
Disposition to Issuer
Performance Stock Units
2010-08-24−25,000→ 0 total
Exercise: $0.00→ Common Stock (25,000 underlying)
Disposition to Issuer
Stock Options
2010-08-24−33,935→ 0 total
Exercise: $13.35→ Common Stock (33,935 underlying)
Disposition to Issuer
Stock Options
2010-08-24−30,000→ 0 total
Exercise: $7.97→ Common Stock (30,000 underlying)

Footnotes (8)

[F1]As the transaction was fully described in the joint proxy statement dated July 14, 2010, as filed with the SEC, each Issuer share was converted into 1.2 shares of common stock of Allscripts Healthcare Solutions, Inc. pursuant to a merger of Issuer with a wholly-owned subsidiary of Allscripts. Shares that were converted included 2,626 shares of Issuer unvested restricted stock that will be subject to the same terms as specified in the original grant. Disposition by Reporting Person was approved by Issuer board of directors.
[F2]In connection with the merger described above, each Issuer option was converted into an option to purchase Allscript common stock equal to 1.2 times the number of Issuer shares subject of the Issuer option and the exercise price was adjusted by dividing the Issuer exercise price by the 1.2 ratio in accordance with the merger agreement. Reporting Person's options were fully vested. Disposition by Reporting Person was approved by Issuer board of directors.
[F3]In connection with the merger described above, each Issuer option was converted into an option to purchase Allscript common stock equal to 1.2 times the number of Issuer shares subject of the Issuer option and the exercise price was adjusted by dividing the Issuer exercise price by the 1.2 ratio in accordance with the merger agreement. Expiration date remains as originally set. Reporting Person's options were vested as to 44,167 Issuer shares. Vesting of the option with respect to the balance of shares will be as specified in the option documents. Disposition by Reporting Person was approved by Issuer board of directors.
[F4]In connection with the merger described above, each Issuer option was converted into an option to purchase Allscript common stock equal to 1.2 times the number of Issuer shares subject of the Issuer option and the exercise price was adjusted by dividing the Issuer exercise price by the 1.2 ratio in accordance with the merger agreement. Expiration date remains as originally set. Reporting Person's options were vested as to 6,875 Issuer shares. Vesting of the option with respect to the balance of shares will be as specified in the option documents. Disposition by Reporting Person was approved by Issuer board of directors.
[F5]In connection with the merger described above, each Issuer option was converted into an option to purchase Allscript common stock equal to 1.2 times the number of Issuer shares subject of the Issuer option and the exercise price was adjusted by dividing the Issuer exercise price by the 1.2 ratio in accordance with the merger agreement. Expiration date remains as originally set. Reporting Person's options were vested as to 8,458 Issuer shares. Vesting of the option with respect to the balance of shares will be as specified in the option documents. Disposition by Reporting Person was approved by Issuer board of directors.
[F6]In connection with the merger described above, each Issuer option was converted into an option to purchase Allscript common stock equal to 1.2 times the number of Issuer shares subject of the Issuer option and the exercise price was adjusted by dividing the Issuer exercise price by the 1.2 ratio in accordance with the merger agreement. Expiration date remains as originally set. Reporting Person's options were vested as to 5,313 Issuer shares. Vesting of the option with respect to the balance of shares will be as specified in the option documents. Disposition by Reporting Person was approved by Issuer board of directors.
[F7]In connection with the merger described above, each Issuer option was converted into an option to purchase Allscript common stock equal to 1.2 times the number of Issuer shares subject of the Issuer option and the exercise price was adjusted by dividing the Issuer exercise price by the 1.2 ratio in accordance with the merger agreement. Expiration date remains as originally set. Reporting Person's options were vested as to 10,625 Issuer shares. Vesting of the option with respect to the balance of shares will be as specified in the option documents. Disposition by Reporting Person was approved by Issuer board of directors.
[F8]Each Performance Stock Unit ("PSU") represented a contingent right to receive a number of shares of Issuer's common stock ranging from 0 to 2.25, depending on the Issuer's Total Shareholder Return ("TSR") compared to the TSRs of a group of pre-selected companies in the healthcare technology and software industries over a performance period commencing on March 15, 2010 and ending on August 24, 2010, the effective date of the merger described above. As a result of the merger, the PSU'swere converted into a fixed number of shares, each of which was converted into 1.2 shares of Allscripts common stock. Disposition by the Reporting Person was approved by Issuer's board of directors.

Documents

1 file

4
doc4.xmlPrimary
FORM 4 SUBMISSION

Issuer

ECLIPSYS CORP

CIK 0001034088

→

Entity typeother

Related Parties

filerCIK 0001441880

Filing Metadata

Form type: 4
Filed: Aug 25, 8:00 PM ET
Accepted: Aug 26, 2:37 PM ET
Size: 34.2 KB

View on SEC.gov